Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer
Metabolic and protein biomarkers in peripheral blood both have high efficacy and reliability in the prediction of immunotherapy sensitivity in unresectable stage III and IV non-small cell lung cancer, but validation in larger population-based cohorts is still needed.
Authors
- Rui Wu (ORCID: https://orcid.org/0000-0002-0797-6845)
- Hao Tang (ORCID: https://orcid.org/0000-0003-1536-1944)
- Yinge Zhou
- Xiao Feng (ORCID: https://orcid.org/0000-0002-7663-7943)
- K. Wei
- Xingshuai Huang
- Xin Dong (ORCID: https://orcid.org/0000-0002-8692-7469)
Institutions
- Shanghai University (CN)
- Second Military Medical University (CN)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Shanghai Changzheng Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-07
- DOI
- https://doi.org/10.3389/fimmu.2025.1479550
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Shanghai Shuguang Program